Table 2. Risk factors for 30-day mortality (n = 267).
| Characteristics | Survival (n = 221) | Mortality (n = 46) | Univariate | Multivariate | |||
|---|---|---|---|---|---|---|---|
| OR | P | OR | P | ||||
| Age (mean, SD) | 57.2, 14.5 | 57.7, 12.9 | N/A | 1.00 | |||
| Male gender (%) | 137 (62.0) | 26 (56.5) | 0.80 (0.42, 1.52) | 0.51 | |||
| Type of cancer | |||||||
| Solid tumors (%) | 123 (55.7) | 22 (47.8) | 0.73 (0.39, 1.38) | 0.34 | |||
| Hematologic malignancies (%) | 105 (47.5) | 26 (56.5) | 1.44 (0.76, 2.72) | 0.33 | |||
| ESBL (%) | 35 (15.8) | 11 (23.9) | 1.67 (0.78, 3.60) | 0.20 | |||
| Comorbidities | |||||||
| DM (%) | 62 (28.1) | 13 (28.3) | 1.01 (0.50, 2.05) | 1.00 | |||
| Chronic liver disease (%) | 15 (6.8) | 6 (13.0) | 2.06 (0.75, 5.63) | 0.22 | |||
| Hematopoietic stem cell transplant (%) | 16 (7.2) | 3 (6.5) | 0.89 (0.25, 3.20) | 1.00 | |||
| Cardiovascular disease (%) | 14 (6.3) | 3 (6.5) | 1.03 (0.28, 3.75) | 1.00 | |||
| Chronic renal disease (%) | 3 (1.4) | 1 (2.2) | 1.62 (0.16, 15.88) | 0.53 | |||
| Neurologic disease (%) | 3 (1.4) | 1 (2.2) | 1.62 (0.16, 15.88) | 0.53 | |||
| Chronic pulmonary disease (%) | 2 (0.9) | 0 (0.0) | N/A | N/A | |||
| Rapidly fatal disease (%) | 63 (28.5) | 15 (32.6) | 1.21 (0.61, 2.40) | 0.60 | |||
| Charlson score (mean, SD) | 4.99, 2.45 | 4.80, 2.54 | N/A | 0.66 | |||
| Risk factors | |||||||
| Neutropenia (%) | 111 (50.2) | 30 (65.2) | 1.86 (0.96, 3.60) | 0.08 | 1.81 | 0.09 | |
| Corticosteroid use (%) | 5 (2.3) | 2 (4.3) | 1.96 (0.37, 10.45) | 0.35 | |||
| Immunosuppressant use (%) | 21 (9.5) | 3 (6.5) | 0.66 (0.19, 2.33) | 0.78 | |||
| Foley catheter (%) | 47 (21.3) | 16 (34.8) | 1.97 (0.99, 3.93) | 0.06 | |||
| Central venous catheter (%) | 116 (52.5) | 26 (56.5) | 1.18 (0.62, 2.23) | 0.63 | |||
| Percutaneous drainage catheter (%) | 21 (9.5) | 6 (13.0) | 1.43 (0.54, 3.76) | 0.43 | |||
| Nasogastric tube (%) | 7 (3.2) | 5 (10.9) | 3.73 (1.13, 12.32) | 0.04 | |||
| Invasive procedure within 7d (%) | 19 (8.6) | 6 (13.0) | 1.60 (0.60, 4.24) | 0.40 | |||
| Surgery within 90 d (%) | 24 (10.9) | 5 (10.9) | 1.00 (0.36, 2.78) | 1.00 | |||
| Mechanical ventilation (%) | 2 (0.9) | 4 (8.7) | 10.43 (1.85, 58.78) | 0.01 | 10.67 | 0.008 | |
| Hemodialysis (%) | 2 (0.9) | 3 (6.5) | 7.64 (1.24, 47.09) | 0.04 | 8.29 | 0.02 | |
| Hospical-acquired infection (%) | 118 (53.8) | 27 (58.7) | 1.24 (0.65, 2.36) | 0.63 | |||
| Severity of infection | |||||||
| Pitt bacteremia score (mean, SD) | 1.53, 1.42 | 2.33, 2.73 | N/A | 0.30 | |||
| Type of infection | |||||||
| Primary bacteremia (%) | 82 (37.1) | 12 (26.1) | 0.59 (0.29, 1.22) | 0.18 | |||
| Catheter-related (%) | 12 (5.4) | 8 (17.4) | 3.67 (1.41, 9.57) | 0.01 | |||
| Urinary tract (%) | 25 (11.3) | 7 (15.2) | 1.41 (0.57, 3.48) | 0.46 | |||
| Pancreatobiliary (%) | 37 (16.7) | 7 (15.2) | 0.89 (0.37, 2.15) | 1.00 | |||
| Intraabdominal (%) | 43 (19.5) | 7 (15.2) | 0.74 (0.31, 1.78) | 0.68 | |||
| Respiratory (%) | 27 (12.2) | 9 (19.6) | 1.75 (0.76, 4.02) | 0.23 | |||
| Skin & soft tissue (%) | 14 (6.3) | 4 (8.7) | 1.41 (0.44, 4.49) | 0.53 | |||
| Others (%) | 2 (0.9) | 1 (2.2) | 2.43 (0.22, 27.41) | 0.43 | |||
| Empirical antibiotic therapy | |||||||
| Inappropriate empirical therapy (%) | 22 (10.0) | 7 (15.2) | 1.62 (0.65, 4.06) | 0.30 | |||
| Piperacillin-tazobactam (%) | 43 (19.5) | 11 (23.9) | 1.30 (0.61, 2.77) | 0.55 | |||
| Third-generation cephalosporins (%) | 43 (19.5) | 6 (13.0) | 0.62 (0.25, 1.56) | 0.40 | |||
| Fourth-generation cephalosporins (%) | 71 (32.1) | 11 (23.9) | 0.66 (0.32, 1.38) | 0.30 | |||
| Aminoglycosides (%) | 0 (0.0) | 1 (2.2) | N/A | N/A | |||
| Fluoroquinolones (%) | 22 (10.0) | 6 (13.0) | 1.36 (0.52, 3.56) | 0.60 | |||
| Carbapenem (%) | 67 (30.3) | 19 (41.3) | 1.62 (0.84, 3.11) | 0.17 | |||
| Glycopeptide (%) | 29 (13.1) | 10 (21.7) | 1.84 (0.83, 4.10) | 0.17 | |||
| Definitive antibiotic therapy | |||||||
| Duration before modification (d; mean, SD) | 4.0, 1.1 | 4.2, 0.9 | N/A | 0.41 | |||
| Inappropriate definitive therapy (%) | 1 (0.4) | 0 (0.0) | N/A | N/A | |||
| Piperacillin-tazobactam (%) | 3 (1.4) | 1 (2.2) | 1.46 (0.14, 14.78) | 0.57 | |||
| Third-generation cephalosporins (%) | 22 (10.0) | 3 (6.5) | 0.51 (0.14, 1.921) | 0.39 | |||
| Fourth-generation cephalosporins (%) | 17 (7.7) | 3 (6.5) | 0.72 (0.19, 2.73) | 0.76 | |||
| Aminoglycosides (%) | 0 (0.0) | 1 (2.2) | N/A | N/A | |||
| Fluoroquinolones (%) | 16 (7.2) | 3 (6.5) | 0.77 (0.20, 3.00) | 1.00 | |||
| Carbapenem (%) | 21 (9.5) | 6 (13.0) | 1.33 (0.45, 3.89) | 0.58 | |||
| Glycopeptides (%) | 1 (0.4) | 1 (2.2) | 4.47 (0.27, 74.76) | 0.34 | |||
OR, odds ratio; SD, standard deviation; N/A, not applicable; ESBL, extended-spectrum beta-lactamase; DM, diabetes mellitus; d, days.